Unternehmensübersicht
Oculis Holding AG operates as a clinical-stage biopharmaceutical entity dedicated to the development of drug candidates designed to address ophthalmic, neuro-ophthalmic, and neurological conditions across Switzerland and international markets. The company functions within the broader Healthcare sector, specifically specializing in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development of novel therapeutic interventions. The total market capitalization stands at $1.43B, while the reported annual revenue for the trailing twelve months is $1.20M, and the employee count is listed as N/A. These valuation and revenue metrics indicate that the company possesses a significant market capitalization relative to its current generated revenue, a profile typical for clinical-stage biotechnology firms where the majority of resources are allocated to pipeline advancement rather than immediate commercialization.
Finanzielle Gesundheit
The company reported revenue of $1.20M over the trailing twelve months, with a net income of $-98,957,000 and an EBITDA of $-81,520,000, revealing a substantial gap where operating costs and R&D expenditures far exceed current revenue generation. Free cash flow stands at $-43,680,624, indicating that the company is currently burning through cash reserves to fund its clinical programs and operational infrastructure. Gross margin is reported at 0.0%, while operating margin reaches -5020.2% and profit margin is 0.0%, figures that reflect the extreme leverage of fixed development costs against minimal sales volume characteristic of the pre-revenue stage. Despite a debt obligation of $2.31M, the company maintains a cash position of $213.01M, resulting in a debt-to-equity ratio of 1.18 which suggests a leveraged balance sheet structure relative to equity. The current ratio of 5.96 demonstrates robust short-term liquidity, indicating that the company holds significantly more current assets than current liabilities to meet its immediate obligations. Return on Equity is -73.5% and Return on Assets is -28.7%, metrics that reveal the company is currently destroying capital value per unit of equity and assets as it invests heavily in its pipeline without yet achieving commercial profitability.
Bewertungsanalyse
The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E stands at -11.72, a negative figure that implies the market is pricing in a lack of immediate earnings potential rather than a traditional earnings trajectory. The price-to-book ratio is 5.85, suggesting that the market values the company's equity at a significant premium over its net book value, likely reflecting the intangible value of its clinical pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 1194.02 and an EV/EBITDA of -14.98 further illustrate that the stock price is decoupled from current financial performance, relying instead on future success assumptions. The 52-week trading range spans from a low of $14.00 to a high of $30.68, and without the specific current share price provided in the facts, the relative position within this range cannot be numerically calculated, though the wide spread indicates high volatility. The beta coefficient is 0.15, which indicates that the stock's price volatility is substantially lower than the broader market, moving with less sensitivity to general market fluctuations despite its biotechnology sector classification.
Growth & Income
Revenue growth year-over-year is reported at an exceptional 13600.0%, while earnings growth is N/A due to the absence of prior year profit figures, meaning that revenue expansion currently outpaces any earnings generation which remains negative. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are retained to fund operations and development rather than distributed to shareholders. The extreme revenue growth figure combined with negative earnings and cash flow highlights a growth-at-all-costs strategy typical of early-stage biotech firms seeking to reach clinical milestones before generating cash. Overall, the company presents a growth-and-income profile defined by aggressive capital expenditure for pipeline development, zero dividend distributions, and valuation multiples that are disconnected from current profitability metrics.